Reading CPIX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CPIX free→Reading CPIX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CPIX free→NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-06-15
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
CPIX shows strong recent financial performance, but it is currently unprofitable, making its earnings quality difficult to assess. Management's track record has been steady, while risk is high and the sector backdrop presents a headwind. Peer multiples imply a price about 8% above where it trades (it looks cheap on this basis); the read is fair, but weakening, as it is priced roughly in line with peers, but recent financials or earnings quality are weakening. The top factors to watch include guidance changes and sector trends, particularly how bellwethers perform. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 3 valuation methods, at three horizons. Current price $5.60. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $5.60 CPIX trades at 2× p/s, below its 3× p/s peer median. Our $6.18 fair value sits above the price; low confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 9% below a flat-multiple fair value, below our forecast of about 13%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted -1.74x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
4 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$226.
How much price usually moves either way.
On a bad day, this stock has moved -$948.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $6,533.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
No named catalysts to watch right now. Check back after the next earnings report.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for CPIX yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
of Form 8-K and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, unless specifically incorporated by reference in a document filed under the Securities Act of 1933, as amended, or the Exchange Act. By filing this report on Form 8-K and furnishing this information, the Company makes no admission as to the materiality of any information in this report that is req…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
No score history yet for this stock.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Roughly priced in line with peers.
Self-history needs ~20 months of data.
Trailing four: 2024-Q3, 2025-Q1, 2025-Q2, 2025-Q3
A side-by-side read on sector standing, valuation, and risk versus Pharmaceuticals.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
CPIX Cumberland Pharmaceuticals Inc | — | fair | high |
LLY Lilly (Eli) | Above typical Show detailsSector percentile: 88 of 100 | expensive | moderate |
JNJ Johnson & Johnson | Above typical Show detailsSector percentile: 74 of 100 | expensive | low |
MRK Merck & Co. | Typical Show detailsSector percentile: 67 of 100 | expensive | moderate |
PFE Pfizer | Typical Show detailsSector percentile: 61 of 100 | fair | low |
Not investment advice. As of 2026-06-15.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Cumberland aims to achieve double-digit revenue growth for the fiscal year 2026.
Newly stated in 2025-Q4. Revenue grew from $8.5M in 2024-Q1 to $16.3M in 2025-Q4, indicating significant progress towards the double-digit growth target. The trajectory shows delivering on growth ambitions.
“achieving the company’s target of double digit revenue growth.”
Cumberland plans to integrate its commercial products with Apotex's U.S. branded business.
Newly stated in 2026-Q1. The strategic transaction with Apotex aims to enhance Cumberland's market presence. While the integration is announced, financial impacts are yet to be realized, indicating early stages of execution.
“entered into a strategic transaction to integrate its commercial products with Apotex.”
Cumberland is addressing litigation challenges related to voting and support agreements.
Newly stated in 2026-Q1. The company is addressing litigation challenges through voting and support agreements. The financial impact of these challenges is not yet clear, indicating ongoing regulatory focus.
“entered into voting and support agreements amid litigation challenges.”
Entry into a Material Definitive Agreement. On April 22, 2026, Cumberland Pharmaceuticals Inc. (the “ Company ” or “ Cumberland ”) entered into a strategic transaction (the “ Transaction ”) to integrate its commercial products with the U.S. branded business of an affiliate of Apotex Inc., a corporation incorporated under the laws of the Province of Ontario (“ Apotex ”), in exchange for $100,000,000 payable at the closing of the Transaction. Through the Transaction Apotex will create a U.S. br…
Other Events . Voting and Support Agreements Simultaneously with the execution of the Agreement, Apotex and the Company entered into voting and support agreements (each, a “ Voting and Support Agreement ”) with certain of the Company’s directors and executive officers who, collectively, hold approximately 41% of the total outstanding shares of common stock of the Company. Pursuant to the Voting and Support Agreements, each shareholder signatory thereto has agreed, with respect to all of the s…
of Form 8-K and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, unless specifically incorporated by reference in a document filed under the Securities Act of 1933, as amended, or the Exchange Act. By filing this report on Form 8-K and furnishing this information, the Company makes no admission as to the materiality of any information in this report that is req…
Entry into a Material Definitive Agreement. On November 18, 2025, Cumberland Pharmaceuticals Inc. (the “Company” or “Cumberland”) and Pinnacle Bank ("Pinnacle") fully executed the First Amendment to Amended and Restated Revolving Credit Note and Second Amendment to Amended and Restated Revolving Credit Loan Agreement (the "Amendment"). The original Pinnacle agreement was dated September 5, 2023. The Amendment provides for a principal available for borrowing of up to $15 million. The Company h…